Table 4.
Subgroup analysis by diameter by follow-up duration, start of baseline period, and diameter at baseline.
| Increase ≥3 mm |
cLNM | pLNM | DTS | DTS Due to Progression |
|
|---|---|---|---|---|---|
| PP (95% C.I.) | PP (95% C.I.) | PP (95% C.I.) | PP (95% C.I.) | PP (95% C.I.) | |
| Follow up duration <2.0 y 2.0–3.4 y ≥3.5 y |
|||||
| 4.9 (5.0–8.0) | 0.8 (0.2–2.8) | 2.0 (0.8–4.7) | 12.9 (10.7–18.6) | 29.7 (8.7–65.1) | |
| 5.9 (3.7–9.3) | 1.4 (0.8–2.5) | 4.2 (2.7–6.5) | 12.9 (6.2–24.8) | 30.6 (25.1–36.6) | |
| 5.5 (3.3–9.2) | 1.2 (0.8–1.7) | 3.6 (3.0–4.2) | 10.7 (8.9–12.9) | 34.1 (20.4–51.0) | |
| Start of baseline period | |||||
| 1993–2010 | 5.3 (3.0–9.4) | 1.2 (0.8–1.9) | 3.7 (3.1–4.4) | 12.7 (10.3–15.7) | 30.5 (20.1–43.2) |
| 2011–2017 | 5.3 (3.6–7.8) | 1.3 (0.8–2.0) | 3.2 (2.2–4.5) | 12.6 (7.9–19.5) | 33.1 (24.7–42.8) |
| Diameter at baseline | |||||
| ≤10 mm | 4.7 (3.3–6.6) | 1.0 (0.8–1.4) | 3.7 (3.2–4.3) | 12.2 (8.5–16.8) | 28.1 (23.5–33.1) |
| ≤20 mm | 7.3 (4.8–11.0) | 1.7 (1.0–2.8) | 2.2 (1.1–4.4) | 13.4 (8.8–19.9) | 37.8 (22.5–56.0) |
PP: pooled proportion, CI: confidence interval, cLNM: clinical lymph node metastases, pLNM: pathological lymph node metastases, DTS: delayed thyroid surgery.